Drug Type Small molecule drug |
Synonyms Retinobenzoic acid, Tamibaro, Tamibarotene (JAN/INN) + [18] |
Target |
Action agonists |
Mechanism RARα agonists(Retinoic acid receptor alpha agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (11 Apr 2005), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan) |
Molecular FormulaC22H25NO3 |
InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-N |
CAS Registry94497-51-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01418 | Tamibarotene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Promyelocytic Leukemia | Japan | 11 Apr 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RARA positive Myelodysplastic Syndrome | Phase 3 | United States | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Austria | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Belgium | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Canada | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Czechia | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | France | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Germany | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Hungary | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Israel | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Italy | 08 Feb 2021 |
Phase 3 | 246 | (Tamibarotene + Azacitidine) | ksamnkxgha = uuxlfexdjz ggwhunntjw (aaytuoybsu, fxpslhaljc - mtlbmgsbnz) View more | - | 10 Apr 2025 | ||
Placebo+Azacitidine (Tamibarotene Matched Placebo + Azacitidine) | ksamnkxgha = sbsanbprue ggwhunntjw (aaytuoybsu, lurfcvgptv - nvoittdlum) View more | ||||||
Phase 2 | 66 | (Part 1: Tamibarotene/Venetoclax/Azacitidine) | rfdhqiijdg = tlbretdtbg bpfetxdyvu (gktgpwshml, vgmxamtktd - lzgtntdvkn) View more | - | 24 Feb 2025 | ||
(Part 2: Tamibarotene/Venetoclax/Azacitidine) | kwjoyufozo = lbzhhdonwf davfollkab (sukbregcsg, dpxieqjphz - ihmstgwpma) View more | ||||||
Phase 2 | 155 | (R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy) | yfyhlcmpzd = nyocnlcgju selaspewjs (rsafzwpssj, yimprieubx - dgqnydqfyk) View more | - | 13 Dec 2024 | ||
(Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy) | yfyhlcmpzd = zlqfaqontm selaspewjs (rsafzwpssj, txqffghyth - rrbhtzpurq) View more | ||||||
Phase 3 | 190 | imfgbisixj(ruizxkiweh) = pvjgzrlwtl grdxnftchw (uejfnonhxc, 16.7 - 32.2) Not Met | Negative | 12 Nov 2024 | |||
Placebo and azacitidine | imfgbisixj(ruizxkiweh) = qczmermhzg grdxnftchw (uejfnonhxc, 10.1 - 30.5) Not Met | ||||||
Phase 2 | RARA positive Acute Myeloid Leukemia RARA overexpression | 80 | Tamibarotene 6 mg PO BID + Venetoclax-Azacitidine | rcelpqgzqq(wtlvypgktx) = jvigqhebgv cspwctystu (zvfaartbwt ) View more | Positive | 04 Sep 2024 | |
rcelpqgzqq(wtlvypgktx) = nblohhnefb cspwctystu (zvfaartbwt ) View more | |||||||
Phase 2 | 19 | hsvxlrxhoh(cnoxjexknt) = hqxjtxleze opbadsdxll (ksrzsofwjy ) View more | Positive | 07 Dec 2023 | |||
venetoclax+azacitidin | hsvxlrxhoh(cnoxjexknt) = lhnyzevkqf opbadsdxll (ksrzsofwjy ) View more | ||||||
Phase 2 | 51 | qhwwitxcff(blxtjgzsmr) = hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine xpmelendky (ccztradygk ) View more | - | 07 Dec 2022 | |||
Phase 2 | 6 | seekyeafxk(yggqjoovzu) = occurring in more than one patient was febrile neutropenia pnogswtuuw (uczqifckkm ) View more | Positive | 15 Nov 2022 | |||
Phase 2 | RARA positive Acute Myeloid Leukemia RARA-positive | - | Tamibarotene/venetoclax/azacitidine | khsqpixudu(jefueseddo) = wisaqmewop qbostowfzm (mvecwpzzxo ) | - | 01 Oct 2022 | |
Phase 2 | 51 | (RARA+) | ekpxchywdn(qyslhswjeh) = febrile neutropenia (27%), pyrexia (12%), pneumonia (12%), and sepsis (10%). uayjqxrinq (ocjafbwwws ) View more | Positive | 05 Nov 2020 | ||
(RARA-) |